Somatic mutational profiling identifies aggressive and indolent disease phenotypes in well-differentiated pancreatic neuroendocrine tumors

Introduction Integration of biomarkers into clinical management of well-differentiated pancreatic neuroendocrine tumors (PNETs) remains limited due to disease rarity and heterogeneity. By utilizing publicly available genomic databases, we’ve established a large cohort of well-differentiated PNETs for study, focusing on somatic mutations and disease subgroup stratification through a modified targeted sequencing approach. Methods A total of 434 patients, representing 310 primary tumors and 124 met